TEM · Tempus AI, Inc.
$67.61
+5.96% last session
End-of-day data · close of 2026-10-23
Market cap
$12B
Enterprise value
$13B
Trailing P/E
—
Forward P/E
-1,435.3
Dividend yield
0.0%
Beta
3.54
Avg volume
7M
Employees
4K
Daily Change %
5.96%
5 Days Change
-1.41%
10 Days Change
-6.46%
30 Days Change
-16.69%
60 Days Change
-3.57%
Month to Day Change
-16.59%
Year to Day Change
8.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TEM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
JP Morgan
Neutral$70.00
+3.5% vs priceGoldman Sachs
Neutral$75.00
+10.9% vs priceUBS
Neutral$70.00
+3.5% vs priceJefferies
Underperform$35.00
-48.2% vs priceMorgan Stanley
Overweight$70.00
+3.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Needham | Reiterates | Buy | $75.00 |
| 2026-10-14 | JP Morgan | Maintains | Neutral | $45.00 → $70.00 |
| 2026-10-12 | Canaccord Genuity | Maintains | Buy | $80.00 → $95.00 |
| 2026-10-01 | Guggenheim | Maintains | Buy | $65.00 → $92.00 |
| 2026-09-21 | Goldman Sachs | Initiates | Neutral | $0.00 → $75.00 |
| 2026-09-11 | HC Wainwright & Co. | Maintains | Buy | $56.00 → $66.00 |
| 2026-09-09 | UBS | Initiates | Neutral | $0.00 → $70.00 |
| 2026-09-08 | Rothschild & Co | Initiates | Neutral | $0.00 → $67.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 2.0% below the 50-day MA ($68.99).
- bullish: Price vs 200-day MA: Trading 19.0% above the 200-day MA ($56.81).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-1.04) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($41.55) and high ($91.58).
TEM Price Chart
Loading chart for TEM…
Fundamentals
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
More in Health Information Services
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.